<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Subclinical hyperthyroidism in nonpregnant adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Subclinical hyperthyroidism in nonpregnant adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Subclinical hyperthyroidism in nonpregnant adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Subclinical hyperthyroidism is defined biochemically as normal serum free thyroxine (T4) and triiodothyronine (T3) concentrations in the presence of a subnormal thyroid-stimulating hormone (TSH) (&lt;0.5 mU/L). The term overt hyperthyroidism refers to patients with elevated levels of free T4, T3, or both and a subnormal TSH concentration. Both subclinical and overt hyperthyroidism are biochemical definitions since hyperthyroid symptoms are nonspecific and may be present in patients with subclinical disease and absent in those with overt disease, especially older adults.</p><p>Subclinical hyperthyroidism in nonpregnant adults will be discussed here. Overt hyperthyroidism and hyperthyroidism during pregnancy are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7847.html" rel="external">"Diagnosis of hyperthyroidism"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7872.html" rel="external">"Graves' hyperthyroidism in nonpregnant adults: Overview of treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7873.html" rel="external">"Treatment of toxic adenoma and toxic multinodular goiter"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7868.html" rel="external">"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7884.html" rel="external">"Hyperthyroidism during pregnancy: Treatment"</a>.)</p><p></p><p class="headingAnchor" id="H793718440"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Several large studies have examined the prevalence of subclinical hyperthyroidism [<a href="#rid1">1-7</a>]. The results of these studies, primarily in subjects over age 55 to 60 years, can be summarized as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>The prevalence of subclinical hyperthyroidism in the community varies between 0.7 and 12.4 percent. This variability is in part due to differences in the definition of low serum TSH values and in the patient populations studied. In the Third National Health and Nutrition Examination Survey (NHANES III) from the United States, which excluded individuals with known thyroid disease, 0.7 percent of 16,533 people had subclinical hyperthyroidism (TSH &lt;0.1 mU/L) [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subclinical hyperthyroidism is more common in areas of the world with mild to moderate iodine deficiency. In addition, subclinical thyroid dysfunction is more common in females, smokers, and older adults [<a href="#rid8">8,9</a>].</p><p></p><p class="headingAnchor" id="H2"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>The causes of subclinical hyperthyroidism are the same as the causes of overt hyperthyroidism, and like overt hyperthyroidism, subclinical hyperthyroidism can be persistent or transient  (<a class="graphic graphic_table graphicRef76972" href="/d/graphic/76972.html" rel="external">table 1</a>). Common causes of subclinical hyperthyroidism include excessive thyroid hormone therapy (exogenous subclinical hyperthyroidism), autonomously functioning thyroid adenomas and multinodular goiters (endogenous subclinical hyperthyroidism), or Graves' disease (endogenous subclinical hyperthyroidism). (See  <a class="medical medical_review" href="/d/html/7871.html" rel="external">"Disorders that cause hyperthyroidism"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Exogenous subclinical hyperthyroidism</span><span class="headingEndMark"> — </span>As many as 10 million people in the United States and possibly as many as 200 million people worldwide are taking thyroid hormone. All are at risk for subclinical hyperthyroidism, whether intentional or unintentional. Among patients taking T4, as many as 25 percent have low serum TSH values [<a href="#rid10">10,11</a>], and in one study, 5.8 percent were under 0.1 mU/L [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/7840.html" rel="external">"Exogenous hyperthyroidism"</a>.)</p><p>Many of these patients have hypothyroidism, and in them, subclinical hyperthyroidism is not the goal of thyroid hormone therapy. However, subclinical hyperthyroidism is the goal of thyroid hormone therapy in patients with thyroid cancer and in some patients with solitary thyroid nodules, multinodular or diffuse goiters, or a history of head and neck irradiation. In these patients, the benefits of TSH suppression are thought to outweigh the risks of subclinical hyperthyroidism. (See  <a class="medical medical_review" href="/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management", section on 'Thyroid hormone suppression'</a> and  <a class="medical medical_review" href="/d/html/7887.html" rel="external">"Thyroid hormone suppressive therapy for thyroid nodules and benign goiter"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Endogenous subclinical hyperthyroidism</span><span class="headingEndMark"> — </span>Autonomously functioning thyroid adenomas and multinodular goiters are the most common causes of endogenous subclinical hyperthyroidism. Among patients over age 55 years, hyperthyroidism due to multinodular goiters was subclinical in 57 percent of patients, while hyperthyroidism due to Graves' disease was subclinical in only 6 percent of patients [<a href="#rid13">13</a>]. In another study, 22 percent of patients with multinodular goiter had subclinical hyperthyroidism, while 28 percent of those with subclinical hyperthyroidism had autonomous area(s) on thyroid imaging [<a href="#rid14">14</a>].</p><p>Subclinical hyperthyroidism also occurs in patients with thyroiditis [<a href="#rid15">15</a>], and it has been reported in 63 percent of clinically euthyroid patients with Graves' ophthalmopathy (euthyroid Graves' disease) [<a href="#rid16">16</a>] and 4 percent of those with Graves' disease in remission [<a href="#rid17">17</a>]. It may also be seen in patients with early Graves' disease prior to the onset of more overt hyperthyroidism. In addition, healthy pregnant women (especially in the first trimester) and those with hyperemesis gravidarum (or trophoblastic disease) who have high serum chorionic gonadotropin concentrations may have subclinical hyperthyroidism. (See  <a class="medical medical_review" href="/d/html/7868.html" rel="external">"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes", section on 'hCG-mediated hyperthyroidism'</a>.)</p><p class="headingAnchor" id="H2302868238"><span class="h1">CLINICAL FINDINGS</span><span class="headingEndMark"> — </span>Most patients with subclinical hyperthyroidism have no clinical manifestations of hyperthyroidism, and those symptoms that are present (eg, tachycardia, tremor, dyspnea on exertion, weight loss) are mild and nonspecific. Many patients have a multinodular goiter with autonomy (toxic nodular goiter) or mild Graves' disease. Most patients are detected through routine screening of thyroid function.</p><p>Subclinical hyperthyroidism is associated with an increased risk of atrial fibrillation and, primarily in postmenopausal women, a decrease in bone mineral density (BMD)  (<a class="graphic graphic_table graphicRef79602" href="/d/graphic/79602.html" rel="external">table 2</a>). (See <a class="local">'Potential consequences of subclinical hyperthyroidism'</a> below.)</p><p class="headingAnchor" id="H2196647488"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of subclinical hyperthyroidism is based upon biochemical testing alone. Subclinical hyperthyroidism is defined as:</p><p class="bulletIndent1"><span class="glyph">●</span>Normal serum free T4 and T3</p><p class="bulletIndent1"><span class="glyph">●</span>Low TSH</p><p></p><p>It may occur in the presence or absence of mild symptoms of hyperthyroidism.</p><p>If the serum TSH concentration is below normal (&lt;0.5 mU/L in many laboratories), the TSH measurement should be repeated along with a serum free T4 and T3 to make the diagnosis of subclinical hyperthyroidism.</p><p>Because the serum TSH concentration can be transiently reduced, a serum TSH measurement, along with a free T4 and T3, should be repeated after one to three months to confirm the diagnosis.</p><p>Once the diagnosis of subclinical hyperthyroidism has been established, the cause should be identified  (<a class="graphic graphic_table graphicRef76972" href="/d/graphic/76972.html" rel="external">table 1</a>). (See <a class="local">'Identifying the cause'</a> below.)</p><p class="headingAnchor" id="H594369163"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Other causes of the combination of low serum TSH and normal free T4 and T3 concentrations include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Central hypothyroidism – Some patients with central hypothyroidism have low serum TSH and normal (but usually low or low-normal) free T4 and T3 concentrations. (See  <a class="medical medical_review" href="/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults", section on 'Secondary and tertiary (central) hypothyroidism'</a> and  <a class="medical medical_review" href="/d/html/7849.html" rel="external">"Central hypothyroidism", section on 'TSH low'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonthyroidal illness – Euthyroid patients with nonthyroidal illness, especially those receiving high-dose glucocorticoids or dopamine, may have low serum TSH and low-normal free T4 and T3 concentrations. (See  <a class="medical medical_review" href="/d/html/7817.html" rel="external">"Thyroid function in nonthyroidal illness"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recovery from hyperthyroidism – Serum TSH concentrations may remain low for up to several months after normalization of serum T4 and T3 concentrations in patients treated for hyperthyroidism or recovering from hyperthyroidism caused by thyroiditis. (See  <a class="medical medical_review" href="/d/html/7872.html" rel="external">"Graves' hyperthyroidism in nonpregnant adults: Overview of treatment", section on 'Thyroid function tests'</a> and  <a class="medical medical_review" href="/d/html/7830.html" rel="external">"Painless thyroiditis", section on 'Laboratory findings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Due to a shift in the distribution of normal TSH values, approximately 3 percent of healthy Black people have a serum TSH &lt;0.4 mU/L, although it would be unusual for the TSH to be &lt;0.1 mU/L [<a href="#rid8">8,18</a>]. This can mimic subclinical hyperthyroidism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ingestion of 5 to 10 mg of <a class="drug drug_general" data-topicid="120386" href="/d/drug information/120386.html" rel="external">biotin</a> can cause artifactually low serum TSH levels in assays using biotin-streptavidin affinity systems in their design [<a href="#rid19">19-21</a>]. Thyroid tests should be repeated at least two days after discontinuation of biotin supplements.</p><p></p><p class="headingAnchor" id="H3494585591"><span class="h1">IDENTIFYING THE CAUSE</span><span class="headingEndMark"> — </span>In patients with risk factors for complications of subclinical hyperthyroidism (eg, age ≥65 years, cardiovascular disease, osteoporosis) and/or with TSH &lt;0.1 mU/L, the cause of subclinical hyperthyroidism should be determined  (<a class="graphic graphic_table graphicRef76972" href="/d/graphic/76972.html" rel="external">table 1</a>) in order to inform management. Patients without risk for complications whose TSH levels are 0.1 mU/L to the lower limit of normal do not require additional evaluation, since observation alone is appropriate management  (<a class="graphic graphic_algorithm graphicRef109938" href="/d/graphic/109938.html" rel="external">algorithm 1</a>). (See <a class="local">'Management'</a> below.)</p><p>Patients at high risk for complications and/or TSH &lt;0.1 mU/L should be questioned about symptoms of hyperthyroidism (eg, tremor, palpitations, heat intolerance), in addition to a past history of thyroid disease, exposure to iodine-containing radiographic contrast media or herbal products containing iodine, use of medications that may suppress TSH (T4, high-dose glucocorticoids), and <a class="drug drug_general" data-topicid="120386" href="/d/drug information/120386.html" rel="external">biotin</a> ingestion. Women of childbearing age should be questioned about the possibility of pregnancy.</p><p>All patients should be examined for the presence of thyroid gland enlargement and/or nodularity.</p><p>In patients not taking T4 or other medications that suppress TSH who have persistently subnormal TSH values, autonomously functioning thyroid adenomas and multinodular goiters are the most common causes of subclinical hyperthyroidism. Graves' disease and thyroiditis are less common.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thyroid testing</strong> – If the diagnosis is not apparent based on the clinical presentation, diagnostic testing is indicated in patients at high risk for complications of subclinical hyperthyroidism in whom we are considering treatment and can initially include any of the following, depending on available expertise and resources (see  <a class="medical medical_review" href="/d/html/7847.html" rel="external">"Diagnosis of hyperthyroidism", section on 'Determining the etiology'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Measurement of thyrotropin receptor antibodies (TRAb, also called TSI, TBII, or TBI). If the antibodies are positive, it confirms the diagnosis of Graves' disease. If negative, it does not distinguish among the etiologies, as TRAb may not be elevated in patients with mild Graves' disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Determination of the radioiodine uptake scan  (<a class="graphic graphic_table graphicRef76972" href="/d/graphic/76972.html" rel="external">table 1</a>). (This can be the initial test or a secondary test in patients with negative TRAb.)</p><p></p><p class="bulletIndent2">If the scan shows one or more focal areas of increased uptake, this could account for the low serum TSH (autonomously functioning thyroid adenoma or multinodular goiter, respectively). If there are focal areas of increased uptake, a thyroid ultrasound would then be useful in delineating the presence of discrete nodules.</p><p></p><p class="bulletIndent2">A high or relatively high 24-hour uptake (relative to the low serum TSH value) that is diffuse is suggestive of Graves' disease.</p><p></p><p class="bulletIndent2">In patients with low or no uptake on radioiodine scan, the etiology of subclinical hyperthyroidism may be thyroiditis or recent iodine exposure.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Measurement of thyroidal artery blood flow on Doppler ultrasonography is useful to distinguish Graves' disease from thyroiditis in overt hyperthyroidism; its utility in subclinical hyperthyroidism has not been validated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other tests</strong> – In postmenopausal women or other patients at risk for osteoporosis, bone densitometry may be useful in making a decision to treat subclinical hyperthyroidism or to monitor. (See  <a class="medical medical_review" href="/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment"</a> and  <a class="medical medical_review" href="/d/html/2035.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women"</a>.)</p><p></p><p class="headingAnchor" id="H1734731501"><span class="h1">POTENTIAL CONSEQUENCES OF SUBCLINICAL HYPERTHYROIDISM</span><span class="headingEndMark"> — </span>Patients with subclinical hyperthyroidism may progress to overt hyperthyroidism. The skeleton and the cardiovascular system are the major target tissues adversely affected by subclinical hyperthyroidism, although abnormalities in other systems have been reported  (<a class="graphic graphic_table graphicRef79602" href="/d/graphic/79602.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H592057356"><span class="h2">Progression to overt hyperthyroidism</span><span class="headingEndMark"> — </span>There are conflicting data regarding the frequency of progression from subclinical to overt hyperthyroidism, with annualized rates of approximately 0.5 to 8 percent [<a href="#rid1">1,4,22-25</a>]. Progression to overt hyperthyroidism appears to be related to the degree of subclinical hyperthyroidism and the underlying disease. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a population-based study from Scotland, 2024 adults with at least two suppressed (&lt;0.4 mU/L) serum TSH levels measured four months apart with normal free or total T4 and total T3 were identified [<a href="#rid25">25</a>]. In the first year of observation, the overall progression rate from subclinical to overt hyperthyroidism was 6.1 percent. For patients with stable subclinical hyperthyroidism who did not progress after one year, progression rates at two, five, and seven years were 0.6, 0.7, and 0.5 percent, respectively. Although the proportion of patients who progressed to overt hyperthyroidism was small, progression was approximately twice as common in patients with serum TSH &lt;0.1 mU/L compared with those with TSH between 0.1 and 0.4 mU/L.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a New Zealand study of 96 patients with endogenous subclinical thyrotoxicosis (TSH &lt;0.25 mU/L), progression to overt hyperthyroidism occurred in 8 percent at one year and increased to 26 percent at five years. At five years, overt hyperthyroidism was seen in 9, 21, and 61 percent of patients whose subclinical hyperthyroidism was due to Graves' disease, nodular goiter, and autonomous nodules, respectively [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a Brazilian study of 48 women &lt;65 years who had TSH ≤0.1 mU/L (confirmed by repeat measurement six to eight weeks later), 20 percent with nodular disease and 40 percent with Graves' disease progressed from subclinical to overt hyperthyroidism over a two-year period [<a href="#rid23">23</a>]. In a separate study of women ≥60 years with only minimal thyrotoxicosis (TSH 0.1 to 0.4 mU/L), progression to overt hyperthyroidism was uncommon (approximately 1 percent yearly) [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study from the United Kingdom, 20.3 percent of patients with subclinical hyperthyroidism and TSH &lt;0.1 mU/L progressed to overt hyperthyroidism over an average of 32 months compared with 6.8 percent of those with TSH 0.1 to 0.39 mU/L [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Framingham Study of adults &gt;60 years with a TSH &lt;0.1 mU/L, only 4.3 percent of patients progressed to overt hyperthyroidism after four years [<a href="#rid1">1</a>].</p><p></p><p>Spontaneous recovery has also been described in patients with subclinical hyperthyroidism. When studied weeks to one year later, 40 to 60 percent of subjects with subclinical hyperthyroidism had normal values [<a href="#rid2">2,4</a>]. This is most likely to occur in subjects with only slightly subnormal serum TSH values (eg, between 0.1 and 0.5 mU/L) when first studied. In an analysis of a primary care network that included 422,242 persons without known thyroid disease, 52 percent who had a serum TSH concentration &lt;0.35 mU/L at baseline had a normal TSH subsequently in the absence of treatment [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Bone and mineral metabolism</span><span class="headingEndMark"> — </span>Thyroid hormone directly stimulates bone resorption, and overt hyperthyroidism is associated with increased bone resorption (and to a lesser extent, low bone formation), low bone density, and an increase in fracture [<a href="#rid28">28</a>]. The changes are greatest in cortical bone (wrist), least in trabecular bone (lumbar spine), and intermediate in mixed cortical-trabecular bone (hip). Endogenous and exogenous subclinical hyperthyroidism are also associated with reduced bone density, particularly in cortical-rich bone in postmenopausal women. The risk of fracture appears to be related to the degree of TSH suppression and to specific patient factors (eg, older age) that confer an increased risk of osteoporotic fracture. This topic is reviewed separately. (See  <a class="medical medical_review" href="/d/html/7882.html" rel="external">"Bone disease with hyperthyroidism and thyroid hormone therapy", section on 'Subclinical hyperthyroidism'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Cardiovascular effects</span><span class="headingEndMark"> — </span>Overt hyperthyroidism is associated with an increased risk of atrial fibrillation, heart failure, pulmonary hypertension, and angina (see  <a class="medical medical_review" href="/d/html/7853.html" rel="external">"Cardiovascular effects of hyperthyroidism"</a>). Patients with subclinical hyperthyroidism also have an increased risk of atrial fibrillation and, in addition, have more subtle cardiac findings including increases in heart rate, cardiac contractility, and left ventricular mass [<a href="#rid29">29,30</a>].</p><p>The presence of cardiovascular findings in subclinical hyperthyroidism is variable, likely due to the degree of TSH suppression, the underlying disease, and individual sensitivity to thyroid hormone excess.</p><p>The degree of TSH suppression that predicts adverse cardiovascular effects is unknown. However, in one small study of exogenous subclinical hyperthyroidism, cardiovascular parameters that were abnormal at higher doses became normal when the dose of T4 was adjusted so that the TSH measured approximately 0.1 mU/L [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H9"><span class="h3">Atrial fibrillation</span><span class="headingEndMark"> — </span>In a meta-analysis of patient-level data from five prospective cohort studies (8711 participants, 810 with endogenous subclinical hyperthyroidism), subclinical hyperthyroidism was associated with an increased risk of atrial fibrillation (hazard ratio [HR] 1.68, 95% CI 1.16-2.43) [<a href="#rid32">32</a>]. The risk was higher for TSH levels &lt;0.1 mU/L compared with 0.1 to 0.44 mU/L (HRs 2.54 versus 1.63).</p><p>The cumulative incidence of atrial fibrillation in patients with subclinical hyperthyroidism is illustrated by the findings of a prospective cohort study of approximately 2000 adults over age 60 years (without atrial fibrillation) followed for 10 years [<a href="#rid7">7</a>]. For subjects with serum TSH values &lt;0.1 mU/L, 0.1 to 0.4 mU/L, or within the normal range, the cumulative incidence of atrial fibrillation was 28, 16, and 11 percent, respectively  (<a class="graphic graphic_figure graphicRef55024" href="/d/graphic/55024.html" rel="external">figure 1</a>) [<a href="#rid7">7</a>].</p><p>In biochemically euthyroid individuals, both serum TSH and free T4 concentrations may also be associated with atrial fibrillation risk. In a population-based study of 1426 subjects, euthyroid individuals with a TSH in the lowest quartile had a higher risk of atrial fibrillation than those in the highest quartile [<a href="#rid33">33</a>]. However, in an analysis of 30,085 individual participant data from 11 prospective cohorts who were euthyroid or had subclinical hypothyroidism, there was no correlation between serum TSH and atrial fibrillation, but serum free T4 concentrations in the highest compared with the lowest quartile was associated with an increased risk of atrial fibrillation (HR 1.45, 95% CI 1.26-1.66) [<a href="#rid34">34</a>].</p><p>Guidelines for the management of atrial fibrillation in patients with hyperthyroidism are discussed separately. (See  <a class="medical medical_review" href="/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation"</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Coronary heart disease</span><span class="headingEndMark"> — </span>In the meta-analysis described above (22,437 participants, 718 with endogenous subclinical hyperthyroidism), the risk of coronary heart disease events was higher in patients with endogenous subclinical hyperthyroidism (HR 1.21, 95% CI 0.99-1.46) [<a href="#rid32">32</a>]. Similar findings were reported in a population-based study from Scotland, which was not included in the meta-analysis [<a href="#rid35">35</a>]. Endogenous subclinical hyperthyroidism was associated with an increased risk of nonfatal cardiovascular disease (HR 1.39, 95% CI 1.22-1.58) [<a href="#rid35">35</a>]. In a 2017 meta-analysis (71,808 participants, 2300 with subclinical hyperthyroidism), the relative risk (RR) for coronary heart disease was 1.20, 95% CI 1.02-1.42 [<a href="#rid36">36</a>]. </p><p>In a group of 322 patients with subclinical hyperthyroidism (mean TSH 0.35 mIU/L) and 1271 euthyroid patients who were undergoing percutaneous coronary intervention, there was no difference in major adverse cardiovascular events (a composite of cardiac mortality, nonfatal myocardial infarction, and target vessel revascularization) [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H1486052135"><span class="h3">Heart failure</span><span class="headingEndMark"> — </span>Subclinical hyperthyroidism is also associated with an increased risk of heart failure [<a href="#rid38">38-40</a>]. In a cohort of older adults aged 70 to 82 years with a history of vascular disease (5316 participants, 71 with subclinical hyperthyroidism, five taking T4), the risk of heart failure over 3.2 years of follow-up was higher compared with euthyroid controls (HR 2.93, 95% CI 1.37-6.24) [<a href="#rid38">38</a>], and in a pooled analysis of individual data from six prospective cohort studies (25,390 participants, 648 with subclinical hyperthyroidism), patients with TSH levels &lt;0.10 mU/L had a higher risk of heart failure than euthyroid controls (16 events in 154 participants [10.4 percent] versus 1762 events in 22,674 [7.8 percent]; HR 1.94, 95% CI 1.01-3.72) [<a href="#rid39">39</a>]. The risk persisted (HR 1.80, 95% CI 1.04-3.13) when those using thyroid hormone were excluded from the analysis.</p><p class="headingAnchor" id="H1484201875"><span class="h3">Other</span><span class="headingEndMark"> — </span>Subclinical hyperthyroidism has several other effects on cardiac function, all similar to but less severe and less frequent than those in overt hyperthyroidism. These include sinus tachycardia, premature atrial complex (PAC; also referred to a premature atrial beat, premature supraventricular complex, or premature supraventricular beat), increase in left ventricular mass index, increase in cardiac contractility, impaired endothelial function, reduced exercise tolerance, reduced heart rate variability, and an increase in markers of coagulation [<a href="#rid29">29,30,41-44</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>There appears to be an increased risk of mortality in patients with subclinical hyperthyroidism. Overall, the increased risk appears to be small but increases with the degree of TSH suppression.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exogenous and endogenous subclinical hyperthyroidism</strong> – In a meta-analysis of five population-based studies examining the association between subclinical hyperthyroidism (both endogenous and exogenous with TSH less than 0.3 to 0.5 mU/L) and cardiovascular and all-cause mortality, the risk for all-cause and cardiovascular mortality was not significant (RRs 1.12, 95% CI 0.89-1.42 and 1.19, 95% CI 0.81-1.76, respectively) [<a href="#rid45">45</a>]. In contrast, two other meta-analyses (both endogenous and exogenous subclinical hyperthyroidism) showed a significantly increased risk of all-cause mortality (HR 1.41, 95% CI 1.12-1.79 and RR 1.27, 95% CI 1.07-1.51, respectively) and coronary heart disease mortality (RR 1.45, 95% CI 1.12-1.86) [<a href="#rid36">36,46</a>]. In a mathematical model designed a priori to explore mortality risk, the excess mortality after diagnosis of subclinical hyperthyroidism depended upon age, with an increase beyond the age of 60 years. However, in a subsequent population-based study, subclinical hyperthyroidism was associated with reduced survival only in individuals &lt;65 years [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endogenous subclinical hyperthyroidism</strong> – Serum T3 levels are higher in patients with endogenous than exogenous subclinical hyperthyroidism, and this may confer a higher mortality risk [<a href="#rid29">29</a>]. In the meta-analysis of 10 prospective cohort studies described above (52,674 participants, 2188 with endogenous subclinical hyperthyroidism) that included only patients with endogenous subclinical hyperthyroidism, there was an increased risk of both total (HR 1.24, 95% CI 1.06-1.46) and cardiovascular (HR 1.29, 95% CI 1.02-1.62) mortality in patients with endogenous subclinical hyperthyroidism [<a href="#rid32">32</a>]. The risk of cardiovascular mortality was higher for TSH levels &lt;0.1 mU/L compared with levels between 0.1 and 0.44 mU/L (HRs 1.84 versus 1.24).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exogenous subclinical hyperthyroidism</strong> – In a study evaluating only patients with exogenous subclinical hyperthyroidism, there was an increased risk of cardiovascular or overall mortality only in patients with fully suppressed TSH levels [<a href="#rid48">48</a>]. In this cohort study of 17,684 patients (mean age 61.6 years) taking T4 replacement therapy, TSH levels were fully suppressed (&lt;0.03 mU/L) or low (0.04 to 0.4 mU/L) in 6 and 21 percent of patients, respectively. Compared with patients with normal TSH, patients with suppressed TSH concentrations (&lt;0.03 mU/L) had increased cardiovascular morbidity and mortality (adjusted HR 1.37, 95% CI 1.17-1.60), whereas those who had serum TSH levels between 0.04 and 0.4 mU/L had a smaller increase in risk that was not significant (adjusted HR 1.10, 95% CI 0.99-1.23).</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Dementia</span><span class="headingEndMark"> — </span>Some [<a href="#rid35">35,49-53</a>], but not all [<a href="#rid54">54-58</a>], case-control and population-based cohort studies suggest that subclinical hyperthyroidism is a risk factor for dementia. A pooled analysis of five prospective cohort studies reported an increased risk of dementia in patients with subclinical hyperthyroidism compared with euthyroidism (adjusted risk ratio 1.67, 95% CI 1.04-2.69) [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/d/html/4836.html" rel="external">"Neurologic manifestations of hyperthyroidism and Graves' disease", section on 'Encephalopathy'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Quality of life</span><span class="headingEndMark"> — </span>Quality of life may be impaired in some patients with subclinical hyperthyroidism, particularly those with endogenous subclinical hyperthyroidism [<a href="#rid29">29</a>]. Variability in findings is likely related to differences in patient populations, duration of subclinical hyperthyroidism, and degree of TSH suppression.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exogenous subclinical hyperthyroidism</strong> – In patients with exogenous subclinical hyperthyroidism, disturbances in sleep and decreases in some physical components have been reported with [<a href="#rid58">58</a>] or without [<a href="#rid56">56,60-62</a>] significant effect on mood or mental health. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In hypothyroid patients randomly assigned to the usual dose of T4 (euthyroid group) versus higher-dose T4 (subclinical hyperthyroid group), the Short Form 36 (SF-36) physical component and general healthy subscale were slightly worse in the subclinical hyperthyroid group [<a href="#rid62">62</a>]. In contrast, mental health, mood, and motor learning were improved.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a six-month, randomized trial of T4 titrated to establish continuation of TSH suppression versus normalization of TSH in 24 patients with a history of differentiated thyroid carcinoma, there were no significant changes in any SF-36 components in either group [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1">On the other hand, in a nonblinded study in which subjects were given a T4 dose that was 50 mcg greater or less than their optimal dose (based on thyrotropin-releasing hormone [TRH]-stimulated TSH testing), patients on the higher dose had improved "well-being" using a visual analog scale compared with baseline [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endogenous subclinical hyperthyroidism</strong> – In patients with endogenous subclinical hyperthyroidism, scores for both the physical and mental health components appear to be lower than in euthyroid control subjects [<a href="#rid64">64</a>]. The low scores were due to symptoms related to thyroid hormone excess (palpitations, nervousness, tremor, and sweating).</p><p></p><p class="headingAnchor" id="H17"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H18"><span class="h2">Patients on T4 for the treatment of hypothyroidism</span><span class="headingEndMark"> — </span>Both low bone density and atrial fibrillation can result in substantial morbidity in older adult patients, and therefore, subclinical hyperthyroidism should be avoided. Patients receiving thyroid replacement therapy who have TSH concentrations below normal should have their dose adjusted to maintain a normal serum TSH concentration (approximately 0.5 to 5.0 mU/L). (See  <a class="medical medical_review" href="/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults", section on 'Older patients or those with coronary heart disease'</a> and  <a class="medical medical_review" href="/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults", section on 'Goals of therapy'</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Patients on suppressive T4 therapy</span><span class="headingEndMark"> — </span>Subclinical hyperthyroidism is unavoidable when thyroid hormone is given to suppress TSH secretion in an attempt to prevent or reduce goiter growth or prevent recurrence of thyroid cancer since it is the goal of therapy. However, the adverse effects of suppressive therapy can be minimized by treatment with the lowest dose of T4 necessary to meet the desired goal [<a href="#rid31">31,65</a>].</p><p>In many, but not all, patients with thyroid cancer, subclinical hyperthyroidism is the goal of thyroid hormone therapy. In these patients, the benefits of TSH suppression are thought to outweigh the risks of subclinical hyperthyroidism. This topic is reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management", section on 'Thyroid hormone suppression'</a>.)</p><p>Candidates for suppressive therapy and goal TSH levels in patients with benign thyroid disease are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/7887.html" rel="external">"Thyroid hormone suppressive therapy for thyroid nodules and benign goiter"</a>.)</p><p>Postmenopausal women taking suppressive doses of thyroid hormone should receive calcium and vitamin D supplementation if needed, and consideration should be given to instituting antiresorptive therapy to prevent bone loss. Drug options for prevention of osteoporosis are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/7882.html" rel="external">"Bone disease with hyperthyroidism and thyroid hormone therapy", section on 'Prevention and treatment of reduced bone density'</a> and  <a class="medical medical_review" href="/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis"</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Endogenous subclinical hyperthyroidism</span><span class="headingEndMark"> — </span>There are few data to guide clinical decisions regarding the treatment of patients with endogenous subclinical hyperthyroidism. We base our decision to treat on clinical risk for complications of subclinical hyperthyroidism and the degree of TSH suppression. In some patients, the values are normal on retesting weeks or months later, such that intervention should not be considered unless persistently low TSH values are documented [<a href="#rid2">2,4</a>].</p><p>Our approach below is largely consistent with guidelines from the American Thyroid Association (ATA) [<a href="#rid66">66</a>] and the European Thyroid Association [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H21"><span class="h3">Patients at high risk for complications</span><span class="headingEndMark"> — </span>In patients at high risk for skeletal or cardiac complications (eg, older patients ≥65 years of age, patients with or at risk for cardiovascular disease, or postmenopausal women with or at risk for osteoporosis), we use the following approach  (<a class="graphic graphic_algorithm graphicRef109938" href="/d/graphic/109938.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>If the serum TSH value is &lt;0.1 mU/L, we treat the underlying cause of subclinical hyperthyroidism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the serum TSH is 0.1 to 0.5 mU/L, we suggest treatment, especially if there is underlying cardiovascular disease, if the bone density is low, or if the patient has hyperthyroid symptoms. We are also more likely to consider treatment if a thyroid radionuclide scan shows one or more focal areas of high uptake (ie, evidence of autonomy) since subclinical hyperthyroidism due to an autonomous nodule is likely to progress to overt hyperthyroidism as the nodule grows.</p><p></p><p class="bulletIndent1">Observation is an alternative in asymptomatic patients, especially in the absence of an autonomous nodule on thyroid scan, in patients with normal bone density, in patients who are taking osteoporosis drugs to reduce bone turnover, and in patients who are taking beta-adrenergic blocking drugs for other reasons. In observed patients, we measure TSH, free T4, and total T3 every six months and obtain bone density measurements every two years.</p><p></p><p class="headingAnchor" id="H22"><span class="h3">Patients at low risk for complications</span><span class="headingEndMark"> — </span>In patients at low risk for complications of hyperthyroidism (eg, individuals &lt;65 years, premenopausal women), we use the following approach  (<a class="graphic graphic_algorithm graphicRef109938" href="/d/graphic/109938.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>If the serum TSH value is persistently &lt;0.1 mU/L, we suggest treating the underlying cause of subclinical hyperthyroidism, especially if the patient has symptoms suggestive of hyperthyroidism and if the patient's thyroid radioiodine scan shows one or more focal areas of increased uptake.</p><p></p><p class="bulletIndent1">Observation is an alternative in asymptomatic patients, especially in the absence of an autonomous nodule on thyroid scan and in patients taking osteoporosis drugs or beta-adrenergic blocking agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the TSH is between 0.1 to 0.5 mU/L, observation alone is appropriate. We measure TSH, free T4, and T3 every six months.</p><p></p><p>Potential benefits of treatment include improvement in certain cardiovascular parameters and in bone mineral density (BMD). However, there are no studies evaluating the long-term benefits of correcting subclinical hyperthyroidism, particularly studies with clinically important endpoints such as cardiovascular disease and fracture. As an example, in a prospective but uncontrolled study of patients with subclinical hyperthyroidism, antithyroid drugs reduced heart rate, premature atrial and ventricular complexes, left ventricular mass index, interventricular septal thickness, and left ventricular posterior wall thickness [<a href="#rid68">68</a>]. Similar improvements in hemodynamic parameters were seen in other studies following radioiodine therapy [<a href="#rid69">69,70</a>].</p><p>In two other nonrandomized studies, postmenopausal women with nodular goiter and subclinical hyperthyroidism treated with antithyroid drugs or radioiodine for two years had higher bone density than similar women who were not treated [<a href="#rid71">71,72</a>].</p><p>Thus, in some patients with subclinical hyperthyroidism, normalization of TSH results in improvement in surrogate outcomes. Long-term clinical trials are required to determine if correcting subclinical hyperthyroidism improves cardiovascular or skeletal outcomes.</p><p class="headingAnchor" id="H23"><span class="h3">Treatment options</span><span class="headingEndMark"> — </span>The treatment options for patients with subclinical hyperthyroidism are the same as those for overt hyperthyroidism and depend upon the underlying etiology. Beta-adrenergic antagonist drugs are useful to control symptoms of adrenergic overactivity (eg, palpitations, tremor). (See  <a class="medical medical_review" href="/d/html/7874.html" rel="external">"Beta blockers in the treatment of hyperthyroidism"</a>.)</p><p>In patients with Graves' disease or nodular thyroid disease with autonomy, treatment options include thionamides, radioiodine, or surgery. The treatment of these conditions is reviewed separately. (See  <a class="medical medical_review" href="/d/html/7872.html" rel="external">"Graves' hyperthyroidism in nonpregnant adults: Overview of treatment"</a> and  <a class="medical medical_review" href="/d/html/7873.html" rel="external">"Treatment of toxic adenoma and toxic multinodular goiter"</a> and  <a class="medical medical_review" href="/d/html/7879.html" rel="external">"Radioiodine in the treatment of hyperthyroidism"</a>.)</p><p>In patients with low or no uptake on radioiodine scan, the etiology of subclinical hyperthyroidism may be thyroiditis, exogenous thyroid hormone intake, or iodine exposure  (<a class="graphic graphic_table graphicRef76972" href="/d/graphic/76972.html" rel="external">table 1</a>). Most patients with thyroiditis and iodine exposure require no treatment since thyroid dysfunction is rarely severe and is transient. However, thyroid tests should be monitored, initially every four to eight weeks, until normalization. Symptomatic patients may benefit from beta-adrenergic antagonists. (See  <a class="medical medical_review" href="/d/html/7830.html" rel="external">"Painless thyroiditis"</a> and  <a class="medical medical_review" href="/d/html/7844.html" rel="external">"Iodine-induced thyroid dysfunction", section on 'Iodine-induced hyperthyroidism'</a>.)</p><p class="headingAnchor" id="H2077159259"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109107.html" rel="external">"Society guideline links: Hyperthyroidism"</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15437.html" rel="external">"Patient education: Hyperthyroidism (overactive thyroid) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2178.html" rel="external">"Patient education: Hyperthyroidism (overactive thyroid) (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/2168.html" rel="external">"Patient education: Antithyroid drugs (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and etiology</strong> – The prevalence of subclinical hyperthyroidism varies between 0.7 and 12.4 percent. It is more common in areas of the world with mild to moderate iodine deficiency. The causes of subclinical hyperthyroidism are the same as the causes of overt hyperthyroidism  (<a class="graphic graphic_table graphicRef76972" href="/d/graphic/76972.html" rel="external">table 1</a>) and include treatment with T4 (exogenous) and autonomously functioning thyroid adenomas and multinodular goiters (endogenous). (See <a class="local">'Epidemiology'</a> above and <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical findings and consequences</strong> – Most patients with subclinical hyperthyroidism have no clinical manifestations of hyperthyroidism, and those symptoms that are present (eg, tachycardia, tremor, dyspnea on exertion, weight loss) are mild and nonspecific. Subclinical hyperthyroidism is associated with an increased risk of atrial fibrillation, coronary heart disease, and heart failure as well as a reduction in bone mineral density (BMD), particularly in cortical-rich bone in postmenopausal women. In addition, patients with subclinical hyperthyroidism may progress to overt hyperthyroidism. Data regarding overall mortality and dementia are variable. (See <a class="local">'Clinical findings'</a> above and <a class="local">'Potential consequences of subclinical hyperthyroidism'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of subclinical hyperthyroidism is based upon biochemical testing alone. Subclinical hyperthyroidism is defined biochemically as normal serum free thyroxine (T4) and triiodothyronine (T3) concentrations in the presence of a subnormal thyroid-stimulating hormone (TSH). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The management of subclinical hyperthyroidism depends upon the underlying etiology. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Overreplacement of thyroid hormone in primary hypothyroidism</strong> – Patients receiving thyroid replacement therapy for the treatment of hypothyroidism and who have TSH concentrations below normal should have their dose adjusted to maintain a normal serum TSH concentration (approximately 0.5 to 5.0 mU/L). (See <a class="local">'Patients on T4 for the treatment of hypothyroidism'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Suppressive thyroid hormone therapy for thyroid cancer</strong> – For patients with thyroid cancer and in some patients with benign nodular thyroid disease, subclinical hyperthyroidism is the goal of thyroid hormone therapy. The adverse effects of suppressive therapy can be minimized by treatment with the lowest dose of T4 necessary to meet the desired goal. (See <a class="local">'Patients on suppressive T4 therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endogenous subclinical hyperthyroidism and high risk for cardiac or skeletal complications</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>TSH &lt;0.1 mU/L</strong> – For patients at high risk for cardiac or skeletal complications (eg, older adults ≥65 years, patients with or at risk for cardiovascular disease, or postmenopausal women with or at risk for osteoporosis) and who have a TSH concentration less than 0.1 mU/L, we recommend treatment of the underlying cause of subclinical hyperthyroidism  (<a class="graphic graphic_algorithm graphicRef109938" href="/d/graphic/109938.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_3" rel="external">Grade 1C</a>). (See <a class="local">'Patients at high risk for complications'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>TSH 0.1 mU/L to lower limit of normal</strong> – For similar patients who have TSH values between 0.1 and 0.5 mU/L, we suggest treatment especially if the bone density is low, if there is underlying cardiovascular disease, if the patient has hyperthyroid symptoms, or if the radionuclide scan shows one or more focal areas of increased uptake (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Observation is an alternative in asymptomatic patients, especially in the absence of an autonomous nodule on thyroid scan, in patients with normal bone density, in patients who are taking osteoporosis drugs to reduce bone turnover, and in patients who are taking beta-adrenergic blocking drugs for other reasons. In observed patients, we measure TSH, free T4, and T3 every six months and obtain a bone density every two years. (See <a class="local">'Patients at high risk for complications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endogenous subclinical hyperthyroidism and low risk for cardiac or skeletal complications</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>TSH &lt;0.1 mU/L</strong> – For patients with endogenous subclinical hyperthyroidism at low risk for cardiac or skeletal complications (young individuals, premenopausal women) and TSH values less than 0.1 mU/L, we suggest treatment, especially if the patient has hyperthyroid symptoms or if the radionuclide scan shows one or more focal areas of increased uptake  (<a class="graphic graphic_algorithm graphicRef109938" href="/d/graphic/109938.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Observation is an alternative in asymptomatic patients, especially in the absence of an autonomous nodule, and in patients taking osteoporosis drugs or beta-adrenergic blocking agents. (See <a class="local">'Patients at low risk for complications'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>TSH 0.1 mU/L to lower limit of normal</strong> – For low-risk patients who have a TSH value between 0.1 and 0.5 mU/L, we suggest observation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We measure TSH, free T4, and T3 every six months.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment options</strong> – For patients selected for active treatment, the treatment options for are the same as those for overt hyperthyroidism and depend upon the underlying etiology. (See <a class="local">'Treatment options'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sawin CT, Geller A, Kaplan MM, et al. Low serum thyrotropin (thyroid-stimulating hormone) in older persons without hyperthyroidism. Arch Intern Med 1991; 151:165.</a></li><li><a class="nounderline abstract_t">Eggertsen R, Petersen K, Lundberg PA, et al. Screening for thyroid disease in a primary care unit with a thyroid stimulating hormone assay with a low detection limit. BMJ 1988; 297:1586.</a></li><li><a class="nounderline abstract_t">Bagchi N, Brown TR, Parish RF. Thyroid dysfunction in adults over age 55 years. A study in an urban US community. Arch Intern Med 1990; 150:785.</a></li><li><a class="nounderline abstract_t">Parle JV, Franklyn JA, Cross KW, et al. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf) 1991; 34:77.</a></li><li><a class="nounderline abstract_t">Franklyn JA, Black EG, Betteridge J, Sheppard MC. Comparison of second and third generation methods for measurement of serum thyrotropin in patients with overt hyperthyroidism, patients receiving thyroxine therapy, and those with nonthyroidal illness. J Clin Endocrinol Metab 1994; 78:1368.</a></li><li><a class="nounderline abstract_t">Sundbeck G, Jagenburg R, Johansson PM, et al. Clinical significance of low serum thyrotropin concentration by chemiluminometric assay in 85-year-old women and men. Arch Intern Med 1991; 151:549.</a></li><li><a class="nounderline abstract_t">Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331:1249.</a></li><li><a class="nounderline abstract_t">Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87:489.</a></li><li><a class="nounderline abstract_t">Belin RM, Astor BC, Powe NR, Ladenson PW. Smoke exposure is associated with a lower prevalence of serum thyroid autoantibodies and thyrotropin concentration elevation and a higher prevalence of mild thyrotropin concentration suppression in the third National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2004; 89:6077.</a></li><li><a class="nounderline abstract_t">De Whalley P. Do abnormal thyroid stimulating hormone level values result in treatment changes? A study of patients on thyroxine in one general practice. Br J Gen Pract 1995; 45:93.</a></li><li><a class="nounderline abstract_t">Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160:526.</a></li><li><a class="nounderline abstract_t">Taylor PN, Iqbal A, Minassian C, et al. Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. JAMA Intern Med 2014; 174:32.</a></li><li><a class="nounderline abstract_t">Díez JJ. Hyperthyroidism in patients older than 55 years: an analysis of the etiology and management. Gerontology 2003; 49:316.</a></li><li><a class="nounderline abstract_t">Rieu M, Bekka S, Sambor B, et al. Prevalence of subclinical hyperthyroidism and relationship between thyroid hormonal status and thyroid ultrasonographic parameters in patients with non-toxic nodular goitre. Clin Endocrinol (Oxf) 1993; 39:67.</a></li><li><a class="nounderline abstract_t">Charkes ND. The many causes of subclinical hyperthyroidism. Thyroid 1996; 6:391.</a></li><li><a class="nounderline abstract_t">Kasagi K, Hatabu H, Tokuda Y, et al. Studies on thyrotrophin receptor antibodies in patients with euthyroid Graves' disease. Clin Endocrinol (Oxf) 1988; 29:357.</a></li><li><a class="nounderline abstract_t">Murakami M, Koizumi Y, Aizawa T, et al. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission. J Clin Endocrinol Metab 1988; 66:103.</a></li><li><a class="nounderline abstract_t">Boucai L, Surks MI. Reference limits of serum TSH and free T4 are significantly influenced by race and age in an urban outpatient medical practice. Clin Endocrinol (Oxf) 2009; 70:788.</a></li><li><a class="nounderline abstract_t">Barbesino G. Misdiagnosis of Graves' Disease with Apparent Severe Hyperthyroidism in a Patient Taking Biotin Megadoses. Thyroid 2016; 26:860.</a></li><li><a class="nounderline abstract_t">Sharma A, Baumann NA, Shah P. Biotin-Induced Biochemical Graves Disease: A Teachable Moment. JAMA Intern Med 2017; 177:571.</a></li><li><a class="nounderline abstract_t">Li D, Radulescu A, Shrestha RT, et al. Association of Biotin Ingestion With Performance of Hormone and Nonhormone Assays in Healthy Adults. JAMA 2017; 318:1150.</a></li><li><a class="nounderline abstract_t">Schouten BJ, Brownlie BE, Frampton CM, Turner JG. Subclinical thyrotoxicosis in an outpatient population - predictors of outcome. Clin Endocrinol (Oxf) 2011; 74:257.</a></li><li><a class="nounderline abstract_t">Rosario PW. The natural history of subclinical hyperthyroidism in patients below the age of 65 years. Clin Endocrinol (Oxf) 2008; 68:491.</a></li><li><a class="nounderline abstract_t">Rosario PW. Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4 mIU/l: a prospective study. Clin Endocrinol (Oxf) 2010; 72:685.</a></li><li><a class="nounderline abstract_t">Vadiveloo T, Donnan PT, Cochrane L, Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): the natural history of endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab 2011; 96:E1.</a></li><li><a class="nounderline abstract_t">Das G, Ojewuyi TA, Baglioni P, et al. Serum thyrotrophin at baseline predicts the natural course of subclinical hyperthyroidism. Clin Endocrinol (Oxf) 2012; 77:146.</a></li><li><a class="nounderline abstract_t">Meyerovitch J, Rotman-Pikielny P, Sherf M, et al. Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. Arch Intern Med 2007; 167:1533.</a></li><li><a class="nounderline abstract_t">Ross DS. Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 1994; 4:319.</a></li><li><a class="nounderline abstract_t">Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008; 29:76.</a></li><li><a class="nounderline abstract_t">Cooper DS, Biondi B. Subclinical thyroid disease. Lancet 2012; 379:1142.</a></li><li><a class="nounderline abstract_t">Mercuro G, Panzuto MG, Bina A, et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab 2000; 85:159.</a></li><li><a class="nounderline abstract_t">Collet TH, Gussekloo J, Bauer DC, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012; 172:799.</a></li><li><a class="nounderline abstract_t">Heeringa J, Hoogendoorn EH, van der Deure WM, et al. High-normal thyroid function and risk of atrial fibrillation: the Rotterdam study. Arch Intern Med 2008; 168:2219.</a></li><li><a class="nounderline abstract_t">Baumgartner C, da Costa BR, Collet TH, et al. Thyroid Function Within the Normal Range, Subclinical Hypothyroidism, and the Risk of Atrial Fibrillation. Circulation 2017; 136:2100.</a></li><li><a class="nounderline abstract_t">Vadiveloo T, Donnan PT, Cochrane L, Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab 2011; 96:1344.</a></li><li><a class="nounderline abstract_t">Sun J, Yao L, Fang Y, et al. Relationship between Subclinical Thyroid Dysfunction and the Risk of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. Int J Endocrinol 2017; 2017:8130796.</a></li><li><a class="nounderline abstract_t">Yang J, Zheng Y, Li C, et al. The Impact of Subclinical Hyperthyroidism on Cardiovascular Prognosis in Patients Undergoing Percutaneous Coronary Intervention. J Clin Endocrinol Metab 2022; 107:986.</a></li><li><a class="nounderline abstract_t">Nanchen D, Gussekloo J, Westendorp RG, et al. Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. J Clin Endocrinol Metab 2012; 97:852.</a></li><li><a class="nounderline abstract_t">Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation 2012; 126:1040.</a></li><li><a class="nounderline abstract_t">Selmer C, Olesen JB, Hansen ML, et al. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab 2014; 99:2372.</a></li><li><a class="nounderline abstract_t">Yavuz DG, Yazici D, Toprak A, et al. Exogenous subclinical hyperthyroidism impairs endothelial function in nodular goiter patients. Thyroid 2008; 18:395.</a></li><li><a class="nounderline abstract_t">Dörr M, Robinson DM, Wallaschofski H, et al. Low serum thyrotropin is associated with high plasma fibrinogen. J Clin Endocrinol Metab 2006; 91:530.</a></li><li><a class="nounderline abstract_t">Demir T, Akinci B, Comlekci A, et al. Levothyroxine (LT4) suppression treatment for benign thyroid nodules alters coagulation. Clin Endocrinol (Oxf) 2009; 71:446.</a></li><li><a class="nounderline abstract_t">Eustatia-Rutten CF, Corssmit EP, Heemstra KA, et al. Autonomic nervous system function in chronic exogenous subclinical thyrotoxicosis and the effect of restoring euthyroidism. J Clin Endocrinol Metab 2008; 93:2835.</a></li><li><a class="nounderline abstract_t">Ochs N, Auer R, Bauer DC, et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 2008; 148:832.</a></li><li><a class="nounderline abstract_t">Haentjens P, Van Meerhaeghe A, Poppe K, Velkeniers B. Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol 2008; 159:329.</a></li><li><a class="nounderline abstract_t">van de Ven AC, Netea-Maier RT, de Vegt F, et al. Associations between thyroid function and mortality: the influence of age. Eur J Endocrinol 2014; 171:183.</a></li><li><a class="nounderline abstract_t">Flynn RW, Bonellie SR, Jung RT, et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab 2010; 95:186.</a></li><li><a class="nounderline abstract_t">Kalmijn S, Mehta KM, Pols HA, et al. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clin Endocrinol (Oxf) 2000; 53:733.</a></li><li><a class="nounderline abstract_t">Tan ZS, Beiser A, Vasan RS, et al. Thyroid function and the risk of Alzheimer disease: the Framingham Study. Arch Intern Med 2008; 168:1514.</a></li><li><a class="nounderline abstract_t">Ceresini G, Lauretani F, Maggio M, et al. Thyroid function abnormalities and cognitive impairment in elderly people: results of the Invecchiare in Chianti study. J Am Geriatr Soc 2009; 57:89.</a></li><li><a class="nounderline abstract_t">Döbert N, Hamscho N, Menzel C, et al. Subclinical hyperthyroidism in dementia and correlation of the metabolic index in FDG-PET. Acta Med Austriaca 2003; 30:130.</a></li><li><a class="nounderline abstract_t">Aubert CE, Bauer DC, da Costa BR, et al. The association between subclinical thyroid dysfunction and dementia: The Health, Aging and Body Composition (Health ABC) Study. Clin Endocrinol (Oxf) 2017; 87:617.</a></li><li><a class="nounderline abstract_t">van der Cammen TJ, Mattace-Raso F, van Harskamp F, de Jager MC. Lack of association between thyroid disorders and Alzheimer's disease in older persons: a cross-sectional observational study in a geriatric outpatient population. J Am Geriatr Soc 2003; 51:884.</a></li><li><a class="nounderline abstract_t">de Jong FJ, den Heijer T, Visser TJ, et al. Thyroid hormones, dementia, and atrophy of the medial temporal lobe. J Clin Endocrinol Metab 2006; 91:2569.</a></li><li><a class="nounderline abstract_t">Roberts LM, Pattison H, Roalfe A, et al. Is subclinical thyroid dysfunction in the elderly associated with depression or cognitive dysfunction? Ann Intern Med 2006; 145:573.</a></li><li><a class="nounderline abstract_t">Moon JH, Ahn S, Seo J, et al. The effect of long-term thyroid-stimulating hormone suppressive therapy on the cognitive function of elderly patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2014; 99:3782.</a></li><li><a class="nounderline abstract_t">Samuels MH, Kolobova I, Smeraglio A, et al. The effects of levothyroxine replacement or suppressive therapy on health status, mood, and cognition. J Clin Endocrinol Metab 2014; 99:843.</a></li><li><a class="nounderline abstract_t">Rieben C, Segna D, da Costa BR, et al. Subclinical Thyroid Dysfunction and the Risk of Cognitive Decline: a Meta-Analysis of Prospective Cohort Studies. J Clin Endocrinol Metab 2016; 101:4945.</a></li><li><a class="nounderline abstract_t">Schlote B, Schaaf L, Schmidt R, et al. Mental and physical state in subclinical hyperthyroidism: investigations in a normal working population. Biol Psychiatry 1992; 32:48.</a></li><li><a class="nounderline abstract_t">Eustatia-Rutten CF, Corssmit EP, Pereira AM, et al. Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial. Clin Endocrinol (Oxf) 2006; 64:284.</a></li><li><a class="nounderline abstract_t">Samuels MH, Schuff KG, Carlson NE, et al. Health status, mood, and cognition in experimentally induced subclinical thyrotoxicosis. J Clin Endocrinol Metab 2008; 93:1730.</a></li><li><a class="nounderline abstract_t">Carr D, McLeod DT, Parry G, Thornes HM. Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. Clin Endocrinol (Oxf) 1988; 28:325.</a></li><li><a class="nounderline abstract_t">Biondi B, Palmieri EA, Fazio S, et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 2000; 85:4701.</a></li><li><a class="nounderline abstract_t">Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 2010; 20:135.</a></li><li><a class="nounderline abstract_t">Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016; 26:1343.</a></li><li><a class="nounderline abstract_t">Biondi B, Bartalena L, Cooper DS, et al. The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. Eur Thyroid J 2015; 4:149.</a></li><li><a class="nounderline abstract_t">Sgarbi JA, Villaça FG, Garbeline B, et al. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab 2003; 88:1672.</a></li><li><a class="nounderline abstract_t">Faber J, Wiinberg N, Schifter S, Mehlsen J. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. Eur J Endocrinol 2001; 145:391.</a></li><li><a class="nounderline abstract_t">Kaminski G, Michalkiewicz D, Makowski K, et al. Prospective echocardiographic evaluation of patients with endogenous subclinical hyperthyroidism and after restoring euthyroidism. Clin Endocrinol (Oxf) 2011; 74:501.</a></li><li><a class="nounderline abstract_t">Mudde AH, Houben AJ, Nieuwenhuijzen Kruseman AC. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol (Oxf) 1994; 41:421.</a></li><li><a class="nounderline abstract_t">Faber J, Jensen IW, Petersen L, et al. Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol (Oxf) 1998; 48:285.</a></li></ol></div><div id="topicVersionRevision">Topic 7881 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1985591" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Low serum thyrotropin (thyroid-stimulating hormone) in older persons without hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3147087" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Screening for thyroid disease in a primary care unit with a thyroid stimulating hormone assay with a low detection limit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2109585" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Thyroid dysfunction in adults over age 55 years. A study in an urban US community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2004476" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8200938" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparison of second and third generation methods for measurement of serum thyrotropin in patients with overt hyperthyroidism, patients receiving thyroxine therapy, and those with nonthyroidal illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1900411" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical significance of low serum thyrotropin concentration by chemiluminometric assay in 85-year-old women and men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7935681" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11836274" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15579761" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Smoke exposure is associated with a lower prevalence of serum thyroid autoantibodies and thyrotropin concentration elevation and a higher prevalence of mild thyrotropin concentration suppression in the third National Health and Nutrition Examination Survey (NHANES III).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7702890" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Do abnormal thyroid stimulating hormone level values result in treatment changes? A study of patients on thyroxine in one general practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10695693" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The Colorado thyroid disease prevalence study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24100714" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12920352" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hyperthyroidism in patients older than 55 years: an analysis of the etiology and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8348708" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prevalence of subclinical hyperthyroidism and relationship between thyroid hormonal status and thyroid ultrasonographic parameters in patients with non-toxic nodular goitre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8936661" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The many causes of subclinical hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2908031" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Studies on thyrotrophin receptor antibodies in patients with euthyroid Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3121661" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18727705" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Reference limits of serum TSH and free T4 are significantly influenced by race and age in an urban outpatient medical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27043844" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Misdiagnosis of Graves' Disease with Apparent Severe Hyperthyroidism in a Patient Taking Biotin Megadoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28192572" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Biotin-Induced Biochemical Graves Disease: A Teachable Moment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28973622" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Association of Biotin Ingestion With Performance of Hormone and Nonhormone Assays in Healthy Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21044113" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Subclinical thyrotoxicosis in an outpatient population - predictors of outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17803710" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The natural history of subclinical hyperthyroidism in patients below the age of 65 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20447066" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4 mIU/l: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20926532" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The Thyroid Epidemiology, Audit, and Research Study (TEARS): the natural history of endogenous subclinical hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22283624" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Serum thyrotrophin at baseline predicts the natural course of subclinical hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17646608" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7833670" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hyperthyroidism, thyroid hormone therapy, and bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17991805" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The clinical significance of subclinical thyroid dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22273398" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Subclinical thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10634380" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22529182" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Subclinical hyperthyroidism and the risk of coronary heart disease and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19001198" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : High-normal thyroid function and risk of atrial fibrillation: the Rotterdam study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29061566" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Thyroid Function Within the Normal Range, Subclinical Hypothyroidism, and the Risk of Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21346066" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29081800" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Relationship between Subclinical Thyroid Dysfunction and the Risk of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Cohort Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34850030" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The Impact of Subclinical Hyperthyroidism on Cardiovascular Prognosis in Patients Undergoing Percutaneous Coronary Intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22238391" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22821943" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24654753" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18399765" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Exogenous subclinical hyperthyroidism impairs endothelial function in nodular goiter patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16303831" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Low serum thyrotropin is associated with high plasma fibrinogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19138314" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Levothyroxine (LT4) suppression treatment for benign thyroid nodules alters coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18397977" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Autonomic nervous system function in chronic exogenous subclinical thyrotoxicosis and the effect of restoring euthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18490668" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18511471" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24801590" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Associations between thyroid function and mortality: the influence of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19906785" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11155096" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18663163" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Thyroid function and the risk of Alzheimer disease: the Framingham Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19054181" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Thyroid function abnormalities and cognitive impairment in elderly people: results of the Invecchiare in Chianti study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15055159" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Subclinical hyperthyroidism in dementia and correlation of the metabolic index in FDG-PET.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28850708" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The association between subclinical thyroid dysfunction and dementia: The Health, Aging and Body Composition (Health ABC) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12757585" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Lack of association between thyroid disorders and Alzheimer's disease in older persons: a cross-sectional observational study in a geriatric outpatient population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16636121" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Thyroid hormones, dementia, and atrophy of the medial temporal lobe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17043339" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Is subclinical thyroid dysfunction in the elderly associated with depression or cognitive dysfunction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25029415" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The effect of long-term thyroid-stimulating hormone suppressive therapy on the cognitive function of elderly patients with differentiated thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24423358" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The effects of levothyroxine replacement or suppressive therapy on health status, mood, and cognition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27689250" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Subclinical Thyroid Dysfunction and the Risk of Cognitive Decline: a Meta-Analysis of Prospective Cohort Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1391296" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Mental and physical state in subclinical hyperthyroidism: investigations in a normal working population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16487438" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18285414" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Health status, mood, and cognition in experimentally induced subclinical thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3139338" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11134131" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20151821" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27521067" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26558232" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12679455" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11580994" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Haemodynamic changes following treatment of subclinical and overt hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21158893" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Prospective echocardiographic evaluation of patients with endogenous subclinical hyperthyroidism and after restoring euthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7955452" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9578817" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
